Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...
Pfizer (NYSE:PFE) Shares Up 2.9% on Earnings Beat
Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings ...
Royalty Pharma plc: Royalty Pharma Reports Q4 and Full Year 2024 Results
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
pharmaphorum6d
Pfizer upgrades Biohaven alliance to a takeover bid
It's worth noting that Biohaven has just reported that sales of Nurtec ODT came in at $124 million ... acquisitions this year, closing a $6.7 billion deal for Arena Pharma and its late-stage ...
Verywell Health on MSN5d
Ubrelvy vs Nurtec: How Do They Compare for Migraines?
Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for acute treatment, while Nurtec can be taken for immediate symptom relief.
Royalty Pharma Announces R&D Funding Collaboration With Biogen
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...